Protagonist Therapeutics Inc (PTGX) - Total Liabilities
Based on the latest financial reports, Protagonist Therapeutics Inc (PTGX) has total liabilities worth $56.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PTGX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Protagonist Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Protagonist Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Protagonist Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bilibili Inc
F:71BA
|
Germany | €25.62 Billion |
|
VEND MARKETPLACES ASA
OL:VEND
|
Norway | Nkr6.00 Billion |
|
MINTH GRP LTD UNSP.ADR/20
F:M3I0
|
Germany | €17.89 Billion |
|
Shanghai Lujiazui Finance & Trade Zone Development Co Ltd A
SHG:600663
|
China | CN¥121.65 Billion |
|
UNIQA Insurance Group AG
VI:UQA
|
Austria | €25.46 Billion |
|
Hess Midstream Partners LP
NYSE:HESM
|
USA | $3.87 Billion |
|
Xinjiang Daqo New Energy Co Ltd
SHG:688303
|
China | CN¥3.06 Billion |
|
Vallourec
PA:VK
|
France | €2.36 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Protagonist Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Protagonist Therapeutics Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Protagonist Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Protagonist Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Protagonist Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $69.43 Million | +226.36% |
| 2023-12-31 | $21.27 Million | -34.18% |
| 2022-12-31 | $32.32 Million | -32.21% |
| 2021-12-31 | $47.67 Million | +6.27% |
| 2020-12-31 | $44.86 Million | -40.15% |
| 2019-12-31 | $74.95 Million | +178.05% |
| 2018-12-31 | $26.96 Million | -37.46% |
| 2017-12-31 | $43.10 Million | +569.81% |
| 2016-12-31 | $6.43 Million | +22.59% |
| 2015-12-31 | $5.25 Million | +121.20% |
| 2014-12-31 | $2.37 Million | -- |
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical tri… Read more